Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~25 mi. (Yvoir, Belgium, +130 more cities)

CHU UCL Namur Site de Godinne ( Site 0103)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~25 mi. (Yvoir, Belgium, +172 more cities)

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~25 mi. (Yvoir, Belgium, +207 more cities)

CHU UCL Namur Site de Godinne ( Site 0706)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~25 mi. (Yvoir, Belgium, +159 more cities)

CHU UCL Namur Site de Godinne ( Site 0354)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~25 mi. (Yvoir, Belgium, +131 more cities)

CHU UCL Namur Site de Godinne ( Site 1005)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

~25 mi. (Yvoir, Belgium, +122 more cities)

CHU UCL Namur Site de Godinne ( Site 1004)

Small Cell Lung Carcinoma

etoposide, +5 more drugs

chemotherapy, +3 more types

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~25 mi. (Yvoir, Belgium, +206 more cities)

Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~25 mi. (Yvoir, Belgium, +96 more cities)

CHU UCL Namur

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

~25 mi. (Yvoir, Belgium, +110 more cities)

Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne

Mantle Cell Lymphoma

rituximab, +1 more drug

immunotherapy, +1 more type

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

~25 mi. (Yvoir, Belgium, +108 more cities)

Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne

HRAS Missense

Head and Neck Squamous Cell Carcinoma

tipifarnib

targeted therapy

Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)

~25 mi. (Yvoir, Belgium, +30 more cities)

Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0102)

Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers

Colorectal Adenocarcinoma

MK-1308A, +4 more drugs

immunotherapy

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

~25 mi. (Yvoir, Belgium, +45 more cities)

CHU Mont-Godinne

Multiple Myeloma, +2 more conditions

CC-92480, +1 more drug

hormone therapy, +1 more type